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Contemporary diabetes management places heavy emphasis on individual responsibility (Meetoo, 2004). 
The lives of people with type 1 diabetes, for 
example, revolve around a temporal regularity 
in which insulin doses must be calculated and 
administered at precise times. Meals, exercise, rest 
and monitoring of blood glucose parameters must 
be planned and performed to match those times 
when insulin levels are expected to drop or peak. 
The perceived complexity of the regimen 
often leads to lapses in adherence. Furthermore, 
non-adherence is often mistakenly attributed to 
inadequate knowledge of diabetes care by ignoring 
psychosocial factors that significantly contribute 
to this problem (Schlundt et al, 1994; Weissberg-
Benchell et al, 1995; Boehm et al, 1997). 
Irrespective of the cause, non-adherence 
is a major problem in diabetes, leading 
to complications and often to subsequent 
hospitalisations, poor clinical outcomes 
and increased healthcare costs (Lau and 
Nau, 2004; Ho et al, 2006). The concept 
of nanotechnology (NT), however, has the 
potential to eradicate non-adherence from 
diabetes care, and to enable millions of people 
with diabetes to lead a more normal life.
Nanotechnology – an overview
NT can be defined as the monitoring, repairing, 
construction and control of human biological 
systems at the cellular level by using materials and 
structures engineered at the molecular level (Kralj 
and Pavelic, 2003). When applied to medicine, 
NT is referred to as nanomedicine – a discipline 
where there are promises of revolutionary 
opportunities to fight against many diseases 
(Logothetidis, 2006).
NT is likely to have a significant impact 
on society, and is perceived as a human affair 
designed to serve human purposes (Schiemann, 
2005). The prefix “nano” originates from the 
Greek word “nanos”, implying 1 billionth of 
a metre (1 nm = 1x10-9 m). To gain a sense of 
proportion, 1 nanometre is about 100 000 times 
smaller than the diameter of a single human hair 
(see Figure 1). At the heart of NT’s promise lies 
the concept of controlling matter at the atomic 
and molecular level. 
It is not surprising that NT is not yet a 
household word, given that it has mainly been 
confined to research laboratories. While the 
term was coined in 1974 by Japanese researcher 
Norio Taniguchi to refer to engineering at length 
scales less than a micrometre, the futurist Eric 
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Drexler is widely credited with popularising the 
term in the mainstream. In his book, Engines of 
Creation, Drexler envisioned a world in which 
tiny machines or “assemblers” will be able to 
build other structures with ultrafine precision 
by physically manipulating individual atoms 
(Drexler, 1986). 
When such a control becomes achievable, 
then atom-by-atom construction of larger 
objects will provide a whole new way of making 
materials, thereby ushering in a second Industrial 
Revolution with even more profound societal 
impacts than the first.
Passionate advocates of NT are keen to 
assert its promise of improved diagnostics and 
therapies with its progressive development 
in fields such as nanoscale surgery, tissue 
engineering and certain types of targeted 
drug therapy (Haberzettl 2002; Emerich and 
Thanos, 2003; Freitas, 2005). In so doing, NT 
will advance broad societal goals, such as better 
health care, increased productivity and improved 
comprehension of nature (Roco, 2003). 
In extending this view, Stix (2001) adds that 
“there has emerged a cult now of futurists who 
foresee NT as a pathway to technological utopia: 
unparalleled prosperity, pollution-free industry 
and even something resembling eternal life”. NT 
will inevitably have huge impacts on health care 
and nursing and yet there is sparse publication on 
the subject in the nursing literature. 
The development of NT is occurring at 
an unprecedented rate. Although still in its 
experimental stage, nanomedicine holds the 
potential to revolutionise the management of 
diabetes, thereby contextualising the notion of 
non-adherence in history. It is useful, therefore, to 
review the potential that nanomedicine has in the 
field of nursing and diabetes care.
Oral insulin
Research into oral administration of insulin 
has been ongoing for several years, and such an 
agent is possibly very close at hand. According to 
Krauland et al (2004), the oral route is considered 
to be the least invasive, and a painless approach 
to diabetes management for individuals whose 
treatment plan depends entirely or partially on 
insulin, thus leading to higher levels of adherence. 
Presently, if taken orally, insulin is denatured 
by adverse pH levels, and undergoes proteolysis by 
enzymes of the gut where the intestinal epithelium 
has a low permeability for large molecules (Carino 
and Mathiowitz, 1999; Owens, 2002). This major 
barrier to the absorption of hydrophilic drugs 
prevents their diffusion into the bloodstream 
(Borchard et al, 1996; Kotzé et al, 1998). 
Consequently, a carrier system, such as 
chitosan, has been used to protect protein 
drugs from gastric enzymes (Ramadas et 
al, 2000) and facilitate the absorption of 
hydrophilic macromolecules (Ward et al, 2000). 
Furthermore, chitosan nanoparticles have been 
found to enhance the intestinal absorption 
of protein molecules to a greater extent than 
aqueous solutions of chitosan in vivo (Agnihotri 
et al, 2004). Chitosan is mucoadhesive, which 
may prolong its residency in the gut and enhance 
permeability by disrupting tight junctions 
between gut epithelial cells, thus allowing 
the drug to reach its ultimate bloodstream 
destination (Lin et al, 2007).
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Figure 1. Examples of nanoscales. Reproduced 
with kind permission of Martin Bennink.
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Glucose monitoring
It is generally accepted that conventional finger-
prick capillary blood glucose self-monitoring is 
associated with major problems. For example, 
Pickup et al (2005) argue that this aspect of 
self-management is painful (leading to non-
adherence), it cannot be performed when the 
person is asleep or driving a vehicle (times when 
the individual is particularly vulnerable to 
hypoglycaemia), and because it is intermittent, it 
can miss dangerous fluctuations in blood glucose 
concentration between tests. Ideally, therefore, 
it would be more acceptable for blood glucose 
monitoring to be continuous and non-invasive.
Several subcutaneously implanted needle-
type enzyme electrodes or microdialysis probes 
for continuous glucose monitoring are close 
to marketing (Mastrototaro, 2000; Maran et 
al, 2002; Garg et al, 2006). However, these 
are limited by their short duration, impaired 
responses and unpredictable signal drift in 
vivo, which contributes to sensor inaccuracies. 
Furthermore, repeated insertion of the sensor 
probe becomes semi-invasive. 
One vision likely to meet the need for 
improved non-invasive glucose monitoring 
in vivo is a “smart tattoo”, which is composed 
of glucose responsive, fluorescence-based 
nanosensors implanted under the skin but 
manipulated from outside. Research is still 
being conducted to rectify the biocompatibility 
and behaviour of this non-invasive device. 
Nanopore immunoisolation devices
In collaboration with Tejal Desai et al (Desai 
et al, 1998), Mauro Ferrari has created one of 
the earliest therapeutically useful nanomedical 
devices applicable to diabetes care. It comprises 
a nano, bio-compatible silicon box composed of 
micromachined nanopores measuring 20 nm 
in diameter. The internal structure has been 
designed to hold healthy pancreatic beta-cells to 
replace those not functioning in the host. 
To overcome the rejection of foreign 
material by the body, Ferrari has constructed a 
nanotechnological membrane placed between 
the transplanting cells and the host organism 
(Desai et al, 1998). The nanopores are large 
enough to allow small molecules, such as 
oxygen, glucose and insulin to pass through, 
but are sufficiently small to impede the passage 
of larger molecules that trigger an immune 
response, thus rendering the device rejection-
free in animal models that have been used. 
By implanting the silicon box under the skin of 
the person with diabetes, it is envisioned that the 
surface biosensors will monitor and counteract 
any rise in the blood glucose level by releasing 
sufficient amounts of insulin, thus converting 
it into glycogen to be stored in the liver. This 
could restore the body’s delicate glucose control 
feedback loop without the need for powerful 
immunosuppresants that can leave the person at 
severe risk of infection (Freitas, 2002).
Artificial nanopancreas
Another possible permanent solution for people 
with diabetes could be the artificial nanopancreas. 
First described in 1974, the idea was based on 
a simple principle: a sensor electrode would 
repeatedly measure blood glucose levels and 
any deviation would be fed back into a small 
computer that energises an infusion pump, which 
would release the required amount of insulin into 
the bloodstream (Hanazaki et al, 2001). The large 
size of this device, however, made it unacceptable 
for anyone to have such an artificial organ. 
NT is now relentless in its attempts to solve 
this problem. Scientists at Metronic MiniMed 
have constructed a nanorobot known as the 
“Long Term Sensor System” (LTSS), which is 
designed to hold insulin in its inner chambers 
and a glucose-level sensor on its surface. In the 
presence of hyperglycaemia, the surface sensors 
are triggered and insulin is released into the 
bloodstream, thereby restoring normoglycaemia 
(Hanazaki et al, 2001; Freitas, 2002; Arya et al, 
2008). Experiments suggest that LTSS has the 
potential to revolutionise diabetes management 
in the near future (Juvenile Diabetes Research 
Federation, 2006).  
The outcome of a successful formula would 
enable both healthcare professionals and 
people with diabetes to review their approach 
to diabetes care. For example, the benefits of 
LTSS would range from the maintenance of 
continuous normal glycaemia, the elimination 
of blood glucose monitoring and the experience 
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of hypoglycaemia and hyperglycaemia, freedom 
from diabetes-related complications to the 
disappearance of chronic immunosuppression as 
in islet transplantation.
Smart cells
Smart-cell technology represents yet another 
development in the management of diabetes. 
In the presence of hyperglycaemia, glucose 
will attack the Smart cell by eating away its 
insulin-containing structure. This damage 
to the cell membrane will break down the 
protein matrix to release insulin and normalise 
blood glucose levels (Aaron, 2003). Smart-cell 
technology implies that endless checking and 
re-checking of blood glucose level will become 
unnecessary, as will injecting insulin.
Implications for nursing
Nursing prides itself on being at the patient’s side 
in times of need, whether in hospital or in the 
community, and the social contract is based on a 
relationship for providing holistic care throughout 
the care continuum. 
Nanomedicine has the potential to redefine 
health and the approach to care delivery. For 
example, in advancing nanomedicine, NT 
promises a transition from treating diseases 
in populations to a more person-centred level, 
dubbed “personalised medicine” (Vlasses and 
Smeltzer, 2007). The implants of nanotransmitters 
and nanosensors would allow individuals to access 
data transmitted from biochips monitoring such 
familial diseases as hypercholesterolaemia. This 
is particularly important when a critical level is 
reached, thereby allowing affected individuals to 
take appropriate action. For people with diabetes, 
a rise in blood glucose level could send a signal 
to the care team to prompt initialisation of a 
customised treatment plan, or nanoparticles could 
be programmed to administer insulin without a 
clinician’s direct intervention.
In time, NT will increasingly become a 
diagnostic and therapeutic enabler to the 
diabetes healthcare team and other healthcare 
professionals, as well as to people with diabetes 
to help take more ownership of their condition. 
The continued development of personalised 
medicine will not only need a time commitment 
from carers, but it will also require a paradigm 
shift from consumers as patients to consumers 
as partners in the decision-making process 
(Ullman-Cullere et al, 2007). 
Arguably, such collaboration is only possible 
if consumers can keep pace with the scientific 
development of NT. In a 2007 survey, 80% 
of consumers had heard very little about 
nanotechnology (ConsumerReportsHealth.
org, 2007). A UK study (Currall et al, 2006) 
found that people expressed a positive attitude 
towards NT when interpreting the term “safe” 
to mean that all risks have been eliminated. 
This erroneous perception suggests the 
need for more communication and public 
education and involvement. 
Furthermore, other issues that currently require 
a debate relate to healthcare professionals and 
consumers who elect not to assume cognitive 
responsibility or are unable to assume this level 
of responsibility. Whether they will be offered 
alternative options or be subjected to any form of 
sanctions remain to be seen. 
The implementation of NT will inevitably 
have ethical implications, although the need 
to develop new ethical guidelines (Thompson, 
2007) due to sparse publications within this 
field (Mnyusiwalla et al, 2003) is contested 
by others. Given the unknown future design 
of NT, Ebbesen and colleagues (2006) are 
nevertheless confident that the open-ended 
nature of Beauchamp and Childress’s (2001) 
principalist model (autonomy, beneficence, non-
maleficence and justice) is sufficiently sensitive 
to address emerging ethical issues in NT.
The advent of NT will present new 
implications for clinicians. The concept 
of routine care could disappear in a world 
where everything is likely to be customised 
for individuals presenting with strange or 
unusual symptoms arising as a consequence of 
nanomaterials being infected with viruses in 
minute software or technology circuits. This 
kind of personalised medicine (Vlasses and 
Smeltzer, 2007) will mean that nurses will need 
to update their knowledge of nanotechnology 
not only for use in the hospital, but also in the 
community. Similarly, safety considerations 
to avoid accidental ingestion of nanomaterials 
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during the delivery of treatments will 
require serious consideration. 
Over-reliance on NT devices could 
also lead healthcare professionals 
to assume that they are receiving 
all the data when in fact that may 
not be the case (Lewis, 2001). 
Technological dependence could reduce 
interprofessional communications, 
while education for students and 
trained practitioners through curricular 
design will be essential to ensure that 
staff are knowledgeable about the 
principles underpinning the safe use of 
nanomaterials. Furthermore, a model 
of care providing round-the-clock NT 
support for consumers and nurses will 
need to be devised and implemented.
The advent of NT means that to reach 
and maintain excellence, healthcare 
professionals will need to be consistent 
in pursuing the required courses in 
advanced technology to deliver care 
(Vlasses and Smeltzer, 2007). NT 
nurses would be actively involved 
in contributing to policy-making 
decisions as well as assisting patients’ 
understanding and consent to use their 
data, protecting privacy and ensuring 
that mechanisms exist that allow them 
to withdraw from any participation. 
Ultimately, however, everyone is likely 
to require an advocate for the safe and 
ethical use of nanomaterials in such 
areas as medical care, the environment, 
industrial health and the fiscal allocation 
of research (Traynor, 2006). NT, 
therefore, has the potential to drive 
down the costs of care and to create 
healthy communities that need to use 
less, rather than more, healthcare.
Nanotoxicology
Nanotoxicology is defined as the 
“science of engineered nanodevices and 
nanostructures that deals with their 
effects in living organisms” (Oberdörster 
et al, 2005). The sparse literature 
available regarding nanotoxicology 
indicates that biodegradable substances 
are normally decomposed and their waste 
products are excreted by the kidneys and 
intestines (Yih and Wei, 2005). 
Evidence, however, suggests that non-
biodegradable nanoparticles accumulate 
particularly in the liver, and the potential 
harm they may trigger, or at what 
dosage, is unclear, thus requiring further 
investigation (Hett, 2004). The finding 
that nanoparticles can provoke increased 
inflammatory responses and potentiate 
the effects of medications is another 
ground for concern (Hampton, 2005). 
Others have found that nanoparticles 
placed near rodents’ nares travelled 
up the olfactory nerves in to the brain, 
thereby crossing the blood–brain barrier 
(Oberdörster et al 2004). 
In the context of protective 
equipment, Gelperina et al (2005) argue 
that surgical gloves, masks and gowns 
may not provide adequate protection, 
thus creating an urgent need for new 
evaluative research before such a 
technology is widely implemented.
Conclusion
There is no doubt that while many of 
these technologies will require rigorous 
testing before being marketed, it is 
not hard to foresee the revolutionary 
approach that is likely to be adopted 
in the management of diabetes and in 
particular type 1 diabetes. 
The discovery of insulin by Banting 
and Best has saved million of lives all 
over the world – diabetes care is due 
a revolution. This important leap to 
embracing NT needs to be taken so that 
progress can continue to be made and 
people with diabetes will be relieved of 
their burden of their condition. NT has 
the potential to revolutionise medicine, 
and hopefully it is just a matter of 
time before the treatment of diabetes is 
overhauled, reversing the current concept 
of non-adherence as an exception rather 
than the norm. n
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